Fig. 4

a Dose-reponse profile of the 5 TKIs tested in HCC78 wild type cells cultured in 2D and b forming spheroids. c Summary of AOC values revealing the increased sensitivity of HCC78 spheroids when treated with lorlatinib (p < 0.001), repotrectinib (p < 0.001), entrectinib (p = 0.002) and ceritinib (p < 0.001). d Fold changes of the AOC obtained from the NGR_fit curves of mutants versus wild type cell lines and e spheroids. The negative signs indicate a decrease in the fold change, whilst positive values reflect an increase in the metric